161 related articles for article (PubMed ID: 23522020)
1. Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Li C; Takahashi C; Zhang L; Huseni M; Stankovich B; Mashhedi H; Lee J; French D; Anderson JE; Kim D; Howell K; Brauer MJ; Kowanetz M; Yan Y; Humke E; Ebens A; Hampton G; Lackner MR; Hegde P; Jia S
J Transl Med; 2013 Mar; 11():76. PubMed ID: 23522020
[TBL] [Abstract][Full Text] [Related]
2. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
3. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Kwei KA; Baker JB; Pelham RJ
PLoS One; 2012; 7(9):e46518. PubMed ID: 23029544
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
5. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events.
Krutzik PO; Nolan GP
Cytometry A; 2003 Oct; 55(2):61-70. PubMed ID: 14505311
[TBL] [Abstract][Full Text] [Related]
6. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.
Martín-Sánchez E; Rodríguez-Pinilla SM; Sánchez-Beato M; Lombardía L; Domínguez-González B; Romero D; Odqvist L; García-Sanz P; Wozniak MB; Kurz G; Blanco-Aparicio C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; García JF; Bischoff JR; Piris MA
Haematologica; 2013 Jan; 98(1):57-64. PubMed ID: 22801959
[TBL] [Abstract][Full Text] [Related]
8. Activation of the MEK-S6 pathway in high-grade ovarian cancers.
Ventura AP; Radhakrishnan S; Green A; Rajaram SK; Allen AN; O'Briant K; Schummer M; Karlan B; Urban N; Tewari M; Drescher C; Knudsen BS
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):499-508. PubMed ID: 20661131
[TBL] [Abstract][Full Text] [Related]
9. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
11. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.
Burrows N; Babur M; Resch J; Ridsdale S; Mejin M; Rowling EJ; Brabant G; Williams KJ
J Clin Endocrinol Metab; 2011 Dec; 96(12):E1934-43. PubMed ID: 21994956
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
[TBL] [Abstract][Full Text] [Related]
13. Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.
Gowan SM; Hardcastle A; Hallsworth AE; Valenti MR; Hunter LJ; de Haven Brandon AK; Garrett MD; Raynaud F; Workman P; Aherne W; Eccles SA
Assay Drug Dev Technol; 2007 Jun; 5(3):391-401. PubMed ID: 17638539
[TBL] [Abstract][Full Text] [Related]
14. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Kong D; Dan S; Yamazaki K; Yamori T
Eur J Cancer; 2010 Apr; 46(6):1111-21. PubMed ID: 20129775
[TBL] [Abstract][Full Text] [Related]
15. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Ramakrishnan V; Kimlinger T; Haug J; Timm M; Wellik L; Halling T; Pardanani A; Tefferi A; Rajkumar SV; Kumar S
Am J Hematol; 2010 Sep; 85(9):675-86. PubMed ID: 20652971
[TBL] [Abstract][Full Text] [Related]
16. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
17. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
[TBL] [Abstract][Full Text] [Related]
18. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
19. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
De P; Dey N; Terakedis B; Bergsagel PL; Li ZH; Mahadevan D; Garlich JR; Trudel S; Makale MT; Durden DL
Cancer Chemother Pharmacol; 2013 Apr; 71(4):867-81. PubMed ID: 23355037
[TBL] [Abstract][Full Text] [Related]
20. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Foster P; Yamaguchi K; Hsu PP; Qian F; Du X; Wu J; Won KA; Yu P; Jaeger CT; Zhang W; Marlowe CK; Keast P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Engell K; Bentzien F; Lam ST; Dale S; Yturralde O; Matthews DJ; Lamb P; Laird AD
Mol Cancer Ther; 2015 Apr; 14(4):931-40. PubMed ID: 25637314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
